» Articles » PMID: 32066470

The Opioid Mortality Epidemic in North America: Do We Understand the Supply Side Dynamics of This Unprecedented Crisis?

Overview
Publisher Biomed Central
Specialty Psychiatry
Date 2020 Feb 19
PMID 32066470
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

While there has been extensive attention to the 'demand side' - or use and adverse consequences, including mortality - of the 'opioid crisis' presently unfolding across North America, few considerations have focused on the supply side. This paper examines the supply side dynamics of this unprecedented public health phenomenon. We provide evidence for several interrelated supply-side elements that have contributed to the present public health crisis. We observe that initially, persistently high levels of prescription opioid availability and use exposed large proportions of the North American population to opioids, resulting in correspondingly high levels of medical and non-medical use (e.g., involving diversion). While various intervention measures to control prescription opioid availability and use have been implemented in recent years, leading to eventual reductions in opioid dispensing levels, these occurred late in the crisis's evolution. Moreover, these supply reductions have not been met by corresponding reductions in opioid use or demand levels. These growing discrepancies between opioid demand and prescription-based sources have left major gaps in opioid supplies. In response to such supply gaps, highly potent and toxic illicit opioid products have rapidly proliferated across North America, and become a core driver of the dramatic spikes in opioid overdose fatality levels in recent years. These supply-related interrelations are corroborated by a corresponding increase in illicit opioid-related fatalities, which arose just as medical opioid supplies began to decrease in many jurisdictions. Improved analyses and understanding of the supply-side dynamics of the opioid crisis are urgently needed in order to inform future intervention and policy development. Meanwhile, the high mortality toll related to illicit, highly toxic opioid exposure requires sustained solutions, including supply-oriented measures (e.g., safer opioid distribution for at-risk users) towards improved public health protection.

Citing Articles

Access and barriers to safer supply prescribing during a toxic drug emergency: a mixed methods study of implementation in British Columbia, Canada.

Urbanoski K, van Roode T, Selfridge M, Hogan K, Fraser J, Lock K Subst Abuse Treat Prev Policy. 2024; 19(1):44.

PMID: 39285270 PMC: 11406709. DOI: 10.1186/s13011-024-00625-7.


Evolution of the substance use landscape: Implications for contingency management.

Goodwin S, Kirby K, Raiff B J Appl Behav Anal. 2024; 58(1):36-55.

PMID: 39193870 PMC: 11803362. DOI: 10.1002/jaba.2911.


Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt.

Min J, Guerra-Alejos B, Yan R, Palis H, Barker B, Urbanoski K JAMA Netw Open. 2024; 7(5):e2411389.

PMID: 38748421 PMC: 11096992. DOI: 10.1001/jamanetworkopen.2024.11389.


Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.

Lundstrom E, Dai Z, Groth C, Hendricks B, Winstanley E, Abate M Subst Abuse Treat Prev Policy. 2024; 19(1):4.

PMID: 38178238 PMC: 10768117. DOI: 10.1186/s13011-023-00587-2.


Shift in hospital opioid use during the COVID-19 pandemic in Brazil: a time-series analysis of one million prescriptions.

Carvalho R, de Magalhaes-Barbosa M, Bianchi L, Rodrigues-Santos G, da Cunha A, Bastos F Sci Rep. 2023; 13(1):17197.

PMID: 37821638 PMC: 10567754. DOI: 10.1038/s41598-023-44533-5.


References
1.
Saloner B, Karthikeyan S . Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. JAMA. 2015; 314(14):1515-7. DOI: 10.1001/jama.2015.10345. View

2.
Kolodny A, Courtwright D, Hwang C, Kreiner P, Eadie J, Clark T . The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015; 36:559-74. DOI: 10.1146/annurev-publhealth-031914-122957. View

3.
Manchikanti L, Helm 2nd S, Fellows B, Janata J, Pampati V, Grider J . Opioid epidemic in the United States. Pain Physician. 2012; 15(3 Suppl):ES9-38. View

4.
Dart R, Surratt H, Cicero T, Parrino M, Severtson S, Bucher-Bartelson B . Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015; 372(3):241-8. DOI: 10.1056/NEJMsa1406143. View

5.
Murphy Y, Goldner E, Fischer B . Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. Pain Physician. 2015; 18(4):E605-14. View